Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-101 in Refractory Weight Gain Post-Bariatric Surgery
NCT05215847Phase 2Completed
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARD-101 in obesity, sponsored by Aardvark Therapeutics, Inc. Primary endpoint: Relative Change in Body Weight (%) at Day 28. Started Mar 2022; status: completed.
02
Drugs
ARD-101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05215847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215847.